Company Encyclopedia
View More
name
Bolt Biotherapeutics
BOLT.US
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc.
1.875 T
BOLT.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking320/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-81.97%E
    • Profit Margin-821.58%E
    • Gross Margin-201.29%E
  • Growth ScoreE
    • Revenue YoY-46.88%E
    • Net Profit YoY34.42%B
    • Total Assets YoY-40.50%E
    • Net Assets YoY-55.43%E
  • Cash ScoreE
    • Cash Flow Margin-12.17%D
    • OCF YoY-46.88%E
  • Operating ScoreE
    • Turnover0.06E
  • Debt ScoreC
    • Gearing Ratio50.65%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Buy Rating for Bolt Biotherapeutics: Innovative Approach and Strong Financials Drive Positive Outlook

    Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating for Bolt Biotherapeutics, citing its innovative approach and strong financials. Bolt's lead asset, BDC-4182, shows superior anti-tumor activity. The company reported a narrower net loss for Q3 2025 and has a strong cash position. Risks include data delays and competitive pressures. Lake Street also reiterated a Buy rating with a $75 price target.

    Tip Ranks·
    US
    BOLT
    +2.56%
    Tip Ranks·
    US
    BOLT
    +2.56%

    Bolt Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.

    benzinga_article·
    US
    BOLT
    +2.56%
    benzinga_article·
    US
    BOLT
    +2.56%

    Bolt Biotherapeutics (BOLT) Gets a Buy from Lake Street

    Lake Street analyst Chad Messer reiterated a Buy rating for Bolt Biotherapeutics, setting a price target of $75. The analyst has an average return of -0.3% and a 38.73% success rate. The general consensus on The Street is a Moderate Buy with a $29.33 average price target for Bolt Biotherapeutics.

    Tip Ranks·
    US
    BOLT
    +2.56%
    Tip Ranks·
    US
    BOLT
    +2.56%

    Bolt Reports Q3 2025 Financial Results And Highlights Progress Across Oncology Pipeline

    Bolt Biotherapeutics, Inc. (BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, today announced its financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update focused on its advancing pipeline.

    rttnews·
    US
    BOLT
    +2.56%
    rttnews·
    US
    BOLT
    +2.56%

    Bolt Biotherapeutics Reports Improved Financial Performance

    Bolt Biotherapeutics, Inc. (BOLT) reported improved Q3 earnings, showing a net loss of $7.1 million, down from $15.2 million a year prior. The company noted decreased collaboration revenue and operating expenses, reflecting a focus on cost management. With a cash position of $17.8 million and short-term investments of $14.2 million, it has a financial runway into 2027. Bolt plans to advance its clinical programs and seek additional capital-raising opportunities to support its operations.

    Tip Ranks·
    US
    BOLT
    +2.56%
    Tip Ranks·
    US
    BOLT
    +2.56%